Cargando…
Pro/Con Debate: Does recombinant factor VIIa have a role to play in the treatment of patients with acute nontraumatic hemorrhage?
Perhaps it is not surprising that in the critical care environment, where lives are frequently on the line, off-label use of certain drugs is relatively common. In general, there are two camps of opinion on this type of utilization. One camp would suggest that potentially life saving products cannot...
Autores principales: | Pieri, Paola, Stein, Deborah M, Scarpelini, Sandro, Rizoli, Sandro |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550936/ https://www.ncbi.nlm.nih.gov/pubmed/16762042 http://dx.doi.org/10.1186/cc4940 |
Ejemplares similares
-
The utility of recombinant factor VIIa as a last resort in trauma
por: Mamtani, Rishi, et al.
Publicado: (2012) -
Recombinant factor VIIA is associated with an improved 24‐hour survival without an improvement in inpatient survival in massively transfused civilian trauma patients
por: Nascimento, Bartolomeu, et al.
Publicado: (2011) -
Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage
por: Kissela, Brett M, et al.
Publicado: (2008) -
Recombinant Activated Factor VIIa Treatment for Refractory Hemorrhage in Infants
por: Dang, Chi N, et al.
Publicado: (2010) -
Recombinant factor VIIa use in patients presenting with intracranial hemorrhage
por: Yampolsky, Natalie, et al.
Publicado: (2014)